Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 257

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 257
---
79,345 10,609 13%246,785 197,377 49,408 25%Other revenue4,922 1,285 3,637 283%11,697 7,837 3,860 49 %Total revenues$94,876 $80,630 $14,246 18%$258,482 $205,214 $53,268 26%

(1) Other revenue primarily includes revenue from our agreement with the DoD.

HEPLISAV-B product revenue increased by $10.6 million and $49.4 million for the three and nine months ended September 30, 2025, respectively, compared to the same periods in 2024. 

For the three and nine months ended September 30, 2025, approximately $3.3 million and $20.6 million of the increase in product revenue, respectively, was due to higher volume, largely driven by continued improvement in market share, and growth in the U.S. hepatitis-B vaccine market. Increases in net sales price contributed approximately $8.2 million and $25.5 million for the three and nine months ended September 30, 2025, respectively, compared to the same periods in 2024. Additionally, adjustments to reserve estimates increased product revenue by approximately $2.4 million for the nine months ended September 30, 2025, compared to the same periods in 2024, primarily due to lower observed HEPLISAV-B return rates.

31

There was no non-U.S. product revenue for each of the three month ending September 30, 2025, and September 30, 2024. For the nine months ended September 30, 2025, and September 30, 2024, non-U.S. product revenue, net included approximately$1.6 million and $2.3 million, respectively. We do not currently anticipate revenue from non-U.S. sales in the near future.

Cost of Sales – Product

Cost of sales - product consists primarily of raw materials, certain fill, finish and overhead costs and any inventory adjustment charges for HEPLISAV-B. 

The following is a summary of our cost of sales - product (in thousands, except for percentages):

 Three Months EndedSeptember 30,Increase from 2024 to 2025Nine Months EndedSeptember 30,Increase from 2024 to 2025Cost of Sales - Product20252024$